Latest News

Ceapro announces Re-election of Board, adoption of amended stock option plan and appointment of President and CEO

EDMONTON, ALBERTA, Canada –(Marketwire-July 9, 2012) – Ceapro Inc. (“Ceapro”or the “Company”) (TSX VENTURE: CZO) announced that Motions carried at the Annual General Meeting of June 25, 2012 include the re-election of Board Members: Ed Taylor as Chairman, Gilles Gagnon, Don Oborowsky, Glenn Rourke, and John Zupancic

Read more

Ceapro Reports First Quarter 2012 Financial Results and provides a corporate update

EDMONTON, ALBERTA–May 28, 2012 – Ceapro Inc. (CZO –V) (“Ceapro” or “the Company”) today released financial results for the quarter ended March 31, 2012 and provided a corporate update. PDF of Ceapro Reports First Quarter 2012 FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2012 Total sales of

Read more

Ceapro Announces Technical Successes on Supercritical Fluid Drying Technology

EDMONTON, ALBERTA, Canada —May 16, 2012 — Ceapro Inc. (TSX-V CZO) is pleased to announce that Dr. Bernhard Seifried from Ceapro presented today the latest results obtained from one of Ceapro’s research programs using a supercritical drying technology. The presentation entitled “Supercritical Fluid Drying of High Molecular Weight Biopolymers for

Read more

Ceapro signs a worldwide licensing agreement for its flagship product with Agriculture and Agri-Food Canada

EDMONTON, ALBERTA – May 8, 2012 – Ceapro Inc. (CZO –V) (“Ceapro” or the Company”) is pleased to announce that it has signed a licensing agreement with AAFC for the sole worldwide rights for all fields of use for an avenanthramide process technology. This innovative technology will

Read more

Ceapro Reports Record Full-Year 2011 Financial and Operating Results

EDMONTON, ALBERTA–April 30, 2012 – Ceapro Inc. (CZO –V) (“Ceapro” or “the Company”) today released financial and operating results for the fiscal year ended December 31, 2011, its first annual financial report under IFRS . FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2011 Total sales

Read more

Ceapro announces a $1.6 million grant from Alberta Innovates Bio Solutions

EDMONTON, ALBERTA – February 27, 2012 – Ceapro Inc. (CZO–V) (“Ceapro” or the Company”) is very pleased to announce the execution of an agreement with Alberta Innovates Bio Solutions who has awarded the Company a $1.6 million grant to establish a state of the art commercial scale

Read more

Ceapro Defends Additional Claim from AVAC Ltd.

Edmonton, Alberta –February 10, 2012 – Ceapro Inc. (CZO – TSX Venture) (“Ceapro” or the “Company”) announced today it and its wholly owned subsidiary, Ceapro Technology Inc. (“CTI”), were served with a Statement of Claim filed in the Court of Queens Bench of Alberta by AVAC Ltd.

Read more

Ceapro Retains Renmark Financial Communications Inc.

EDMONTON, ALBERTA, Canada —February 3, 2012 — Ceapro Inc. (TSX-V CZO) is pleased to announce that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities. “We are pleased to announce that we have selected Renmark to reinforce Ceapro’s profile in

Read more

Ceapro Announces $370,000 of Convertible Debentures Converted to Equity

EDMONTON, ALBERTA, Canada —January 3, 2012 — Ceapro Inc. (TSX-V CZO) today announced that holders of $370,000 of the convertible debentures due December 31, 2011 have elected to convert their debentures into common shares at a conversion price of 10 cents per common share. This will result

Read more

Ceapro provides Update to Shareholders

Edmonton, AB–(Marketwire – December 6, 2011) – The following is a letter to shareholders from Ceapro Inc. Dear Shareholders: At Ceapro (TSXV: CZO) we are very pleased with our year to date 2011 financial results showing profitability and continuous improvement in our balance sheet. Significantly these results

Read more
Page 10 of 12« First...89101112